Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Long-Term Deferred Tax (2019 - 2022)

Madrigal Pharmaceuticals (MDGL) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $271.1 million as the latest value for Q4 2022.

  • Quarterly Long-Term Deferred Tax changed N/A to $271.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $271.1 million through Dec 2022, changed N/A year-over-year, with the annual reading at $271.1 million for FY2022, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2022 was $271.1 million at Madrigal Pharmaceuticals, up from $132.4 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $271.1 million in Q4 2022, with the low at $65.9 million in Q4 2019.
  • Average Long-Term Deferred Tax over 3 years is $156.5 million, with a median of $132.4 million recorded in 2020.
  • Peak annual rise in Long-Term Deferred Tax hit 101.05% in 2020, while the deepest fall reached 101.05% in 2020.
  • Over 3 years, Long-Term Deferred Tax stood at $65.9 million in 2019, then skyrocketed by 101.05% to $132.4 million in 2020, then skyrocketed by 104.77% to $271.1 million in 2022.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $271.1 million, $132.4 million, and $65.9 million for Q4 2022, Q4 2020, and Q4 2019 respectively.